'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Cipla has increased 5.58% to Rs 7051.02 crore. Sales of Phamaceuticals segment has gone up 5.01% to Rs 6,775.56 crore (accounting for 95.50% of total sales). Sales of New Ventures segment has gone up 21.17% to Rs 319.60 crore (accounting for 4.50% of total sales). Inter-segment sales rose Rs 38.16 crore to Rs 44.14 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 11.38% to Rs 1,804.46 crore. PBIT of Phamaceuticals segment rose 8.19% to Rs 1,780.73 crore (accounting for 98.68% of total PBIT). PBIT of New Ventures reported profit of Rs 23.73 crore compared to loss of Rs 25.87 crore.
PBIT margin of Phamaceuticals segment rose from 25.51% to 26.28%. PBIT margin of New Ventures segment rose...
Pleaselogin & subscribe to view the full report.
More Reports
-
(01-Mar-2025)
Foseco India
OP up 17%
-
(28-Feb-2025)
Schaeffler India
Maintains double digit revenue growth and stable OPM
-
(28-Feb-2025)
Sanofi India
OP up 18.78%
-
(28-Feb-2025)
KSB
Net up 33% largely on higher sales, higher OI and lower taxation
|
|